Posters and mini-orals include another VEGF bispecific.
ApexOnco Front Page
Recent articles
Interius, one of the most advanced players, will cost $350m.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
But the former is paying a fraction of what Merck shelled out for raludotatug.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
